Among these leptin antagonists, only LPrA2 has been certified as effective in the decrease of leptin-induced effects in breast cancer patients with multidrug resistance to sunitinib, doxorubicin, cisplatin, and paclitaxel [170,171]. Here, LEP is linked to breast carcinoma.